The initiative is in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community.
The report urges that we need increased awareness of lupus amongst the general public, people living with lupus, their families and healthcare providers to help those with the condition feel acknowledged, understood and supported. Also, improved access to specialist, multidisciplinary clinics and greater awareness of clinical trials to enable better research.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs